Mostrar el registro sencillo del ítem

dc.contributor.authorClemens, Sue Ann Costapt_BR
dc.contributor.authorSprinz, Eduardopt_BR
dc.contributor.authorVoysey, Merrynpt_BR
dc.contributor.authorPollard, Andrew J.pt_BR
dc.contributor.authorArns, Beatrizpt_BR
dc.contributor.authorCunha, Debora Rosilei Miquini de Freitaspt_BR
dc.contributor.authorDias, Ana Luiza Perez Olivept_BR
dc.contributor.authorPinheiro, Jéssica Morgana Gedielpt_BR
dc.contributor.authorSorio, Guilherme Geraldo Lovatopt_BR
dc.contributor.authorStein, Ricardopt_BR
dc.contributor.authorVieceli, Tarsilapt_BR
dc.contributor.authorVieira, Taiane Alvespt_BR
dc.contributor.authorZimmer, Rafael Lealpt_BR
dc.contributor.authorThe AMPHEUS Projectpt_BR
dc.contributor.authorOxford COVID Vaccine Trial Grouppt_BR
dc.date.accessioned2022-04-07T04:47:52Zpt_BR
dc.date.issued2021pt_BR
dc.identifier.issn2041-1723pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/236682pt_BR
dc.description.abstractSeveral COVID-19 vaccines have shown good efficacy in clinical trials, but there remains uncertainty about the efficacy of vaccines against different variants. Here, we investigate the efficacy of ChAdOx1 nCoV-19 (AZD1222) against symptomatic COVID-19 in a post-hoc exploratory analysis of a Phase 3 randomised trial in Brazil (trial registration ISRCTN89951424). Nose and throat swabs were tested by PCR in symptomatic participants. Sequencing and genotyping of swabs were performed to determine the lineages of SARS-CoV-2 circulating during the study. Protection against any symptomatic COVID-19 caused by the Zeta (P.2) variant was assessed in 153 cases with vaccine efficacy (VE) of 69% (95% CI 55, 78). 49 cases of B.1.1.28 occurred and VE was 73% (46, 86). The Gamma (P.1) variant arose later in the trial and fewer cases (N = 18) were available for analysis. VE was 64% (−2, 87). ChAdOx1 nCoV-19 provided 95% protection (95% CI 61%, 99%) against hospitalisation due to COVID-19. In summary, we report that ChAdOx1 nCoV-19 protects against emerging variants in Brazil despite the presence of the spike protein mutation E484K.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofNature Communications. London. Vol. 12 (2021), 5861, 10 p.pt_BR
dc.rightsOpen Accessen
dc.subjectDoenças transmissíveispt_BR
dc.subjectInfectious diseasesen
dc.subjectVaccinesen
dc.subjectSARS-CoV-2pt_BR
dc.subjectCOVID-19pt_BR
dc.subjectSARS-CoV-2en
dc.subjectViral infectionen
dc.subjectVacinas contra COVID-19pt_BR
dc.subjectCarga viralpt_BR
dc.titleEfficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazilpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001137336pt_BR
dc.type.originEstrangeiropt_BR


Ficheros en el ítem

Thumbnail
Thumbnail
Thumbnail
Thumbnail
   

Este ítem está licenciado en la Creative Commons License

Mostrar el registro sencillo del ítem